Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley
This article was originally published in The Pink Sheet Daily
Dubbed the "G20 Project," the Beijing Leap-forward Development Program for Biopharmaceutical Industry seeks to transform the capital city into China's hub for biotech R&D and manufacturing.
You may also be interested in...
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In the last installment, we took a closer look at Sanofi SA and Merck & Co., in this edition we drill down on Novo Nordisk A/S, Roche Holdings AG and GlaxoSmithKline PLC ('Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1),' PharmAsia News, Aug. 8, 2011).
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority. For Sanofi SA, more than one-third of its global sales now hail from EMs. Merck invested more than $100 million in EMs in Q2 while it announced it will cut back on its sales force in developed markets.
Merck & Co. affiliate MSD has invested an undisclosed amount of debt and equity financing in the Beijing-based start-up biotech BeiGene, Ltd., BeiGene announced May 2